Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

146 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.
Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, Tam E, Marinho RT, Tsai N, Nyberg A, Box TD, Younes Z, Enayati P, Green S, Baruch Y, Bhandari BR, Caruntu FA, Sepe T, Chulanov V, Janczewska E, Rizzardini G, Gervain J, Planas R, Moreno C, Hassanein T, Xie W, King M, Podsadecki T, Reddy KR; PEARL-III Study; PEARL-IV Study. Ferenci P, et al. Among authors: gervain j. N Engl J Med. 2014 May 22;370(21):1983-92. doi: 10.1056/NEJMoa1402338. Epub 2014 May 4. N Engl J Med. 2014. PMID: 24795200 Free article. Clinical Trial.
In routine clinical practice, few physicians use early viral kinetics to guide HCV dual therapy treatment decisions.
Mangia A, Bányai T, De Bartolomeo G, Gervain J, Habersetzer F, Mulkay JP, Ouzan D, Parruti G, Passariello N, Remy AJ, Rizzetto M, Shiffman ML, Tice AD, Schmitz M, Tatsch F, Rodriguez-Torres M. Mangia A, et al. Among authors: gervain j. Liver Int. 2014 Aug;34(7):e217-28. doi: 10.1111/liv.12352. Epub 2013 Nov 20. Liver Int. 2014. PMID: 24251988
IL28B and IL10R -1087 polymorphisms are protective for chronic genotype 1 HCV infection and predictors of response to interferon-based therapy in an East-Central European cohort.
Pár A, Pár G, Tornai I, Szalay F, Várszegi D, Fráter E, Papp M, Lengyel G, Fehér J, Varga M, Gervain J, Schuller J, Nemes Z, Péterfi Z, Tusnádi A, Hunyady B, Haragh A, Szinku Z, Vincze A, Szereday L, Kisfali P, Melegh B. Pár A, et al. Among authors: gervain j. BMC Res Notes. 2014 Jan 8;7:12. doi: 10.1186/1756-0500-7-12. BMC Res Notes. 2014. PMID: 24398031 Free PMC article.
Ombitasvir/paritaprevir/ritonavir + dasabuvir + ribavirin in HCV genotype 1 infected patients who failed previous protease inhibitor therapy.
Hunyady B, Abonyi M, Gerlei Z, Gervain J, Horváth G, Jancsik V, Lengyel G, Makkai E, Pár A, Péter Z, Pusztay M, Ribiczey P, Rókusz L, Sarrazin C, Schneider F, Susser S, Szalay F, Tornai I, Tusnádi A, Újhelyi E, Werling K, Makara M. Hunyady B, et al. Among authors: gervain j. Clin Exp Hepatol. 2018 Jun;4(2):83-90. doi: 10.5114/ceh.2018.75957. Epub 2018 May 25. Clin Exp Hepatol. 2018. PMID: 29904724 Free PMC article.
[Protocol for the treatment of chronic viral hepatitis].
Dalmi L, Gervain J, Hunyady B, Ibrányi E, Makara M, Pár A, Szalay F, Tornai I, Telegdy L. Dalmi L, et al. Among authors: gervain j. Orv Hetil. 2006 Dec 24;147(51):2481-4. Orv Hetil. 2006. PMID: 17378168 Hungarian. No abstract available.
[Efficacy and safety of boceprevir based triple therapy in Hungarian patients with hepatitis C genotype 1 infection, advanced stage fibrosis and prior treatment failure].
Hunyady B, Abonyi M, Csefkó K, Gervain J, Haragh A, Horváth G, Jancsik V, Makkai E, Müller Z, Ribiczey P, Sipos B, Szabó O, Szalay F, Szentgyörgyi L, Tornai I, Újhelyi E, Varga M, Weisz G, Makara M. Hunyady B, et al. Among authors: gervain j. Orv Hetil. 2016 Aug;157(34):1366-74. doi: 10.1556/650.2016.30538. Orv Hetil. 2016. PMID: 27546804 Hungarian.
146 results